Floatz logo

ENCENICLINE

Central Nervous System Diseases

FORUM Pharmaceuticals IncSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Central Nervous System Diseases cohort.

Asset / SponsorPhaseRating
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
Donanemab
Eli Lilly and Company
Phase 3BB
LEVODOPA
Merck Sharp & Dohme LLC
Phase 2B

View all 50 →

Same molecule, other indications

ENCENICLINE is also rated in:

Impaired CognitionDormant
BB
Indicative ·
66 / 100
View asset →
schizophreniaDormant
B
Indicative ·
62 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →